🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Italy / NCT06699095
Active, not recruiting Not applicable

Home Rehabilitation as Continuity of Care in MS

NCT06699095 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-11-06
Last updated
2026-09-01

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Telerehabilitation

Telerehabilitation: Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.

Study summary

RCT pilot study to evaluate adherence, satisfaction and feasibility in the use of a telemedicine station for balance rehabilitation in patients with multiple sclerosis.

The platform is designed as a tool for maintenance rehabilitation in a home setting and not as an alternative to intensive treatment in hospital, and is therefore compared to maintenance treatment as usual (TAU) after intensive treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Expanded Disability Status Scale score between 3 and 6 * Sensory Organisation Test Equitest values indicating balance impairment Exclusion Criteria: * visual impairments * orthopedic impairments * inability to perform balance rehabilitation in stand up position

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
IRCCS Istituto Auxologico Italiano Milan MI
Fondazione IRCCS Istituto Neurologico Carlo Besta Milan MI
IRCCS Santa Maria nascente - Fondazione Don Gnocchi Milan MI

More Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06699095 on ClinicalTrials.gov ↗ ← All trials in Italy